Biohaven Pharmaceuticals Inc.

Psychiatric Disorders

Biohaven Pharmaceuticals Inc. is active in clinical research for Obsessive Compulsive Disorder, with studies centered on patients who have not responded adequately to standard SSRI and related antidepressant treatments.

  • Obsessive Compulsive Disorder
  • Treatment-resistant symptoms
  • Adjunctive therapy

The sponsor’s psychiatric research includes evaluation of symptom improvement and longer-term safety and tolerability in individuals living with persistent compulsive and intrusive symptoms.

Neuromuscular Disease

Biohaven also supports research in Spinal Muscular Atrophy, focusing on functional outcomes in participants receiving established disease-modifying treatments such as nusinersen and risdiplam.

  • Spinal Muscular Atrophy
  • Motor function
  • Neuromuscular impairment

These studies examine changes in physical performance and mobility-related measures in a chronic motor neuron disorder.

Central Nervous System Therapeutics

The sponsor’s portfolio reflects interest in central nervous system conditions where persistent symptoms affect daily functioning and quality of life, particularly in neuropsychiatric and neurologic disease settings.

  • Neuropsychiatric disorders
  • Neurologic disorders
  • Functional outcome assessment

Research activity spans symptom control, functional change, and treatment response in disorders with substantial unmet medical need.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on Troriluzole for Patients with Obsessive Compulsive Disorder Not Responding to Current Treatment

    Not recruiting

    1 1
    Investigated drugs:
    Italy Spain
  • Long-Term Safety Study of Troriluzole for Patients with Obsessive Compulsive Disorder Not Responding to SSRI, Clomipramine, Venlafaxine, or Desvenlafaxine

    Not recruiting

    1 1 1
    Investigated drugs:
    Italy Spain
  • Study of Taldefgrobep Alfa for Patients with Spinal Muscular Atrophy on Stable Nusinersen and/or Risdiplam Regimen or with Onasemnogene Abeparvovec-xioi History

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Germany Italy The Netherlands Poland +1